معرفی
Yang Yun-Gui is a Professor at the Beijing Institute of Genomics, Chinese Academy of Sciences (CAS), holding this position since November 2008. He concurrently serves as Assistant Director of the Beijing Institute of Genomics since December 2019 and Head of the Education Program for Life Science Engineering and Informatics at the Sino-Danish College, CAS since January 2015.
His academic foundation includes a B.Sc in Microbiology from Fudan University (1995) and a Ph.D. in Biochemistry and Molecular Biology from the Shanghai Institute of Materia Medica, CAS (2000). He completed extensive postdoctoral training at the International Agency for Research on Cancer in Lyon, France (2000-2005) and Clare Hall Laboratories in London under Nobel Laureate Tomas Lindahl (2005-2008).
Dr. Yang's research spans DNA repair mechanisms, RNA methylation dynamics, epitranscriptomics, cancer biology, and chemical biology. He pioneered discoveries on DNA repair proteins (NBS1/FANCA/PARP1) and identified Trex1 exonuclease's critical role in degrading ssDNA to prevent innate immune activation. His current work focuses on mapping epitranscriptomic RNA modifications, particularly dynamic RNA methylation patterns in disease contexts.
His accolades include:
- 2019 Jiazhen Tan Life Science Innovation Award
- Consecutive Excellent Supervisor Awards (2018, 2019)
- State Council Special Government Allowance (2018)
- National "Millions Talent Plan" Award (2017)
- Top 10 Life Science Advances of China (2017)
- National Science Fund for Distinguished Young Scholars (2016)
- "100-Talents" Program Excellence Award (2014)
As an educator, he received the Zhu Li Yuehua Outstanding Teacher Award (2013) and CAS-BHPB Mentor Research Award (2012). His research is funded by elite programs including the National Science Fund for Distinguished Young Scholars and Millions Talent Plan. Dr. Yang leads advisory roles in national funding agencies and academic societies while directing research initiatives at the Beijing Institute of Genomics focused on RNA modification therapeutics.
